MX352564B - Compuestos heterociclos biciclicos y sus usos en terapia. - Google Patents

Compuestos heterociclos biciclicos y sus usos en terapia.

Info

Publication number
MX352564B
MX352564B MX2013012243A MX2013012243A MX352564B MX 352564 B MX352564 B MX 352564B MX 2013012243 A MX2013012243 A MX 2013012243A MX 2013012243 A MX2013012243 A MX 2013012243A MX 352564 B MX352564 B MX 352564B
Authority
MX
Mexico
Prior art keywords
bicyclic heterocycle
therapy
compounds
heterocycle compounds
tautomeric
Prior art date
Application number
MX2013012243A
Other languages
English (en)
Other versions
MX2013012243A (es
Inventor
Steven Howard
Christopher Norbert Johnson
Thomas Daniel Heightman
Alison Jo-Anne Woolford
Ildiko Maria Buck
Gianni Chessari
Emiliano Tamanini
James Edward Harvey Day
Elisabetta Chiarparin
Martyn Frederickson
Charlotte Mary Griffiths-Jones
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of MX2013012243A publication Critical patent/MX2013012243A/es
Publication of MX352564B publication Critical patent/MX352564B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos heterociclos biciclicos de fórmula (1):(Ver Formula) o formas tautoméricas o estereoquímicamente isoméricas, N-óxidos, sus sales farmacéuticamente aceptables o sus solvatos; en donde R1, Ra2, R2b, R3a, R3b, R5, R6, R7, R8, R9, p y E son como se encuentran definidos en la presente; a composiciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2013012243A 2011-04-21 2012-04-20 Compuestos heterociclos biciclicos y sus usos en terapia. MX352564B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477726P 2011-04-21 2011-04-21
GBGB1106817.8A GB201106817D0 (en) 2011-04-21 2011-04-21 New compound
PCT/GB2012/050867 WO2012143726A1 (en) 2011-04-21 2012-04-20 Bicyclic heterocycle compounds and their uses in therapy

Publications (2)

Publication Number Publication Date
MX2013012243A MX2013012243A (es) 2014-01-23
MX352564B true MX352564B (es) 2017-11-28

Family

ID=44147398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012243A MX352564B (es) 2011-04-21 2012-04-20 Compuestos heterociclos biciclicos y sus usos en terapia.

Country Status (28)

Country Link
US (6) US9018214B2 (es)
EP (2) EP3868747A1 (es)
JP (1) JP6100238B2 (es)
KR (1) KR101896134B1 (es)
CN (1) CN103492376B (es)
AR (2) AR086468A1 (es)
AU (1) AU2012246081B2 (es)
BR (1) BR112013027121B8 (es)
CA (1) CA2831346C (es)
CY (1) CY1123991T1 (es)
DK (1) DK2699562T3 (es)
ES (1) ES2855171T3 (es)
GB (1) GB201106817D0 (es)
HR (1) HRP20210450T1 (es)
HU (1) HUE053688T2 (es)
IL (1) IL228923A (es)
LT (1) LT2699562T (es)
MX (1) MX352564B (es)
MY (1) MY168159A (es)
NZ (1) NZ615572A (es)
PL (1) PL2699562T3 (es)
PT (1) PT2699562T (es)
RU (1) RU2662827C2 (es)
SG (1) SG193542A1 (es)
SI (1) SI2699562T1 (es)
TW (1) TWI558698B (es)
WO (1) WO2012143726A1 (es)
ZA (1) ZA201307797B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
TWI649319B (zh) * 2013-12-20 2019-02-01 英商阿斯迪克治療公司 雙環雜環化合物及其治療用途
RU2697512C2 (ru) 2014-05-22 2019-08-15 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она и 1,3-дигидро-пирроло[3,2-c]пиридин-2-она
AU2015279377B2 (en) 2014-06-26 2019-09-12 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CA2957566C (en) 2014-08-12 2023-08-01 Daniel Paul Becker Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
AU2015357167B2 (en) 2014-12-03 2020-06-25 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo(1,5-alpha)pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
US10967078B2 (en) 2014-12-03 2021-04-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2 PET ligands
EP3760625B1 (en) * 2015-07-02 2024-03-27 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
PL3389727T3 (pl) 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET
CA3003962A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
BR112018071408A2 (pt) * 2016-04-20 2019-02-05 Glaxosmithkline Ip Dev Ltd “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
EP3455221B1 (en) * 2016-05-09 2020-03-11 H. Hoffnabb-La Roche Ag Dimeric compounds
CN108690005B (zh) * 2018-06-26 2021-08-24 兰州大学 含硝基天然产物chrysamides B合成方法及其非对映异构体-化合物
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
CN111072549A (zh) * 2018-10-19 2020-04-28 中国科学院兰州化学物理研究所苏州研究院 一种手性氧化吲哚螺环茚酮化合物及其合成方法
US20220144850A1 (en) * 2019-02-02 2022-05-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
JP2023523854A (ja) 2020-05-04 2023-06-07 大塚製薬株式会社 Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法
TW202210490A (zh) * 2020-06-04 2022-03-16 英屬開曼群島商百濟神州有限公司 作為IAP拮抗劑的吡啶並[2,3-b][1,4]噁嗪或四氫吡啶並[2,3-b][1,4]氧氮呯
CA3211638A1 (en) * 2021-03-10 2022-09-15 Marina VIRGILI-BERNADO New 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives as sigma ligands
TW202346295A (zh) * 2022-03-11 2023-12-01 大陸商蘇州亞盛藥業有限公司 作為iap拮抗劑的三環雜環化合物
WO2024071371A1 (ja) * 2022-09-30 2024-04-04 ユビエンス株式会社 複素環式化合物
CN118027138A (zh) * 2022-11-07 2024-05-14 南京中澳转化医学研究院有限公司 吡啶酮类化合物及其制备方法、药物组合物和应用
WO2024179529A1 (zh) * 2023-02-28 2024-09-06 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途
CN116253756B (zh) * 2023-05-11 2023-07-18 北京元延医药科技股份有限公司 克立硼罗的制备方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
TW218875B (es) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE69628804T2 (de) 1995-12-08 2003-12-18 Pfizer Inc., New York Substitutierte heterozyclische Derivate als CRF Antagonisten
PT892780E (pt) 1996-02-22 2003-02-28 Bristol Myers Squibb Pharma Co Analogos de m-amidino fenilo como inibidores do factor xa
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
CA2257950A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NZ500252A (en) 1997-04-18 2001-07-27 Smithkline Beecham P 6-(4-Methyl-piperazin-1-yl)-1H-indole derivatives useful as 5HT1A, 5HT1B and 5HT1D receptor antagonists
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
US6557977B1 (en) 1997-07-15 2003-05-06 Silverbrook Research Pty Ltd Shape memory alloy ink jet printing mechanism
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
KR20010041341A (ko) * 1998-02-26 2001-05-15 해피 페너 ; 해리 에이치. 페너 2세 벤질피페라지닐 및 벤질피페리디닐 에탄온 유도체, 이의제조 방법 및 도파민 ｄ４ 수용체 길항제로서의 이의 용도
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
NZ525108A (en) 1998-03-31 2005-02-25 Acadia Pharm Inc Compounds with activity on muscarinic receptors
EP1114028B1 (en) 1998-08-26 2006-11-29 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2000055143A1 (en) 1999-03-17 2000-09-21 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1354882A1 (en) 2000-12-27 2003-10-22 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
US6790845B2 (en) 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
AU2003235097A1 (en) 2002-04-24 2003-11-10 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
RU2333200C2 (ru) 2003-03-07 2008-09-10 Астеллас Фарма Инк. Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1653960A4 (en) 2003-08-13 2008-11-26 Amgen Inc MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
EP2253614B1 (en) 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
WO2006014361A1 (en) 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
KR101317661B1 (ko) 2005-02-25 2013-10-15 테트랄로직 파마슈티칼스 코포레이션 이량체성 ｉａｐ 억제제
EP1948639A2 (en) 2005-11-11 2008-07-30 F. Hoffmann-la Roche AG Novel carbocyclic fused cyclic amines
KR20080080203A (ko) 2005-12-19 2008-09-02 제넨테크, 인크. Ｉａｐ의 억제제
US7674802B2 (en) 2005-12-21 2010-03-09 Decode Genetics, Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
GB0608184D0 (en) * 2006-04-25 2006-06-07 Astex Therapeutics Ltd Pharmaceutical compounds
US20100016340A1 (en) 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
KR101071516B1 (ko) * 2006-05-05 2011-10-10 더 리젠츠 오브 더 유니버시티 오브 미시간 2가 ｓｍａｃ 모방체 및 그의 용도
CL2007002166A1 (es) 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
MX2009003834A (es) 2006-10-12 2009-04-22 Novartis Ag Derivados de pirrolidina como inhibidores de iap.
CN101535273B (zh) 2006-12-07 2012-04-11 诺瓦提斯公司 治疗增生性疾病的6-氧代-1,6-二氢嘧啶-2-基化合物
MX2009009541A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
ES2504216T3 (es) * 2007-04-13 2014-10-08 The Regents Of The University Of Michigan Miméticos de Smac diazo bicíclicos y sus usos
JP5298128B2 (ja) * 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
WO2009067233A1 (en) 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
WO2009094287A1 (en) 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
JP5628841B2 (ja) 2009-02-27 2014-11-19 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビター
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
WO2010138666A1 (en) * 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2013052110A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
EP2800738B1 (en) 2012-01-06 2020-04-08 Novartis AG Heterocyclic compounds and methods for their use
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
TWI649319B (zh) 2013-12-20 2019-02-01 英商阿斯迪克治療公司 雙環雜環化合物及其治療用途
CA2935944A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
KR20230006541A (ko) 2020-05-04 2023-01-10 오츠카 세이야쿠 가부시키가이샤 무수 락트산을 합성하는 방법
JP2023523854A (ja) 2020-05-04 2023-06-07 大塚製薬株式会社 Ｉａｐアンタゴニスト化合物及びその中間体、並びにそれを合成する方法

Also Published As

Publication number Publication date
EP3868747A1 (en) 2021-08-25
CN103492376B (zh) 2015-07-22
GB201106817D0 (en) 2011-06-01
US20210122749A1 (en) 2021-04-29
CA2831346C (en) 2021-04-13
RU2662827C2 (ru) 2018-07-31
AR086468A1 (es) 2013-12-18
BR112013027121A2 (es) 2017-01-03
SG193542A1 (en) 2013-10-30
CN103492376A (zh) 2014-01-01
ZA201307797B (en) 2019-02-27
US20140179666A1 (en) 2014-06-26
TWI558698B (zh) 2016-11-21
BR112013027121B1 (pt) 2022-03-03
US20240199607A1 (en) 2024-06-20
CA2831346A1 (en) 2012-10-26
HRP20210450T1 (hr) 2021-04-30
EP2699562B1 (en) 2020-12-23
AU2012246081B2 (en) 2017-01-05
ES2855171T3 (es) 2021-09-23
WO2012143726A1 (en) 2012-10-26
TW201309673A (zh) 2013-03-01
AR116993A2 (es) 2021-06-30
IL228923A0 (en) 2013-12-31
US20190375748A1 (en) 2019-12-12
PT2699562T (pt) 2021-03-25
DK2699562T3 (da) 2021-03-01
BR112013027121B8 (pt) 2023-01-31
PL2699562T3 (pl) 2021-06-14
KR101896134B1 (ko) 2018-09-07
KR20140032405A (ko) 2014-03-14
SI2699562T1 (sl) 2021-07-30
IL228923A (en) 2017-12-31
HUE053688T2 (hu) 2021-07-28
US20170334907A1 (en) 2017-11-23
LT2699562T (lt) 2021-04-26
AU2012246081A1 (en) 2013-10-03
JP2014514317A (ja) 2014-06-19
EP2699562A1 (en) 2014-02-26
US9018214B2 (en) 2015-04-28
RU2013151803A (ru) 2015-05-27
MY168159A (en) 2018-10-11
NZ615572A (en) 2015-02-27
MX2013012243A (es) 2014-01-23
JP6100238B2 (ja) 2017-03-22
CY1123991T1 (el) 2022-05-27
US20150291586A1 (en) 2015-10-15
US11866428B2 (en) 2024-01-09
US9676768B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
MX352564B (es) Compuestos heterociclos biciclicos y sus usos en terapia.
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12015502056A1 (en) Benzothiazole compounds and their pharmaceutical use
IN2015DN01156A (es)
MX2014005304A (es) Biaril eter sulfonamidas y su uso como agentes terapeuticos.
MX349004B (es) Nuevos compuestos.
UA117590C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
MX343706B (es) Derivados heterocíclicos novedosos.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX2015007796A (es) Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
PH12015500376A1 (en) Novel bicyclic pyridinones
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TW201613864A (en) Novel compounds
MY159756A (en) Nitrile derivatives and their pharmaceutical use and compositions
MY169215A (en) 3-o-heteroaryl-ingenol
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
TN2013000327A1 (en) Novel heterocyclic derivatives

Legal Events

Date Code Title Description
FG Grant or registration